Tags

Type your tag names separated by a space and hit enter

Postoperative phosphodiesterase type 5 inhibitor administration increases the rate of urinary continence recovery after bilateral nerve-sparing radical prostatectomy.
Int J Urol. 2013 Apr; 20(4):413-9.IJ

Abstract

OBJECTIVES

To investigate the effect of phosphodiesterase type 5 inhibitor on urinary continence recovery after bilateral nerve-sparing radical prostatectomy.

METHODS

We analyzed data of 393 open bilateral nerve-sparing radical prostatectomies carried out between 2005 and 2010. Patients who recovered urinary continence within the first month after catheter removal (n = 52) were excluded. This resulted in 341 evaluable patients. Urinary continence recovery was defined as being completely pad free over a period of 24 h. Patients were stratified according to postoperative daily (n = 58; 17%), on-demand (n = 112; 32.8%) and no (n = 171; 50.1%) phosphodiesterase type 5 inhibitor use. The effect of phosphodiesterase type 5 inhibitor use on urinary continence was assessed using the Kaplan-Meier method. Uni- and multivariable Cox regression analyses were used to test the association between phosphodiesterase type 5 inhibitor and urinary continence recovery after adjusting for cofounders.

RESULTS

At a mean follow up of 36.4 months after surgery (median: 33), 288 patients (84.5%) recovered urinary continence after bilateral nerve-sparing radical prostatectomy. Patients who did not use phosphodiesterase type 5 inhibitor after surgery had lower rates of urinary continence recovery at 1- and 2-year follow up as compared with patients taking phosphodiesterase type 5 inhibitor (67.1 vs 86.7% and 76 vs 94.4%, respectively; P < 0.001). After adjusting for all confounders, multivariable analysis showed that phosphodiesterase type 5 inhibitor use, either on demand or daily, had a positive impact on urinary continence recovery (P = 0.03).

CONCLUSIONS

Patients taking phosphodiesterase type 5 inhibitor have higher urinary continence recovery rates as compared with patients left untreated after bilateral nerve-sparing radical prostatectomy. An improvement in sphincteric and pelvic floor blood supply might be responsible for this beneficial effect associated with the use of phosphodiesterase type 5 inhibitor.

Authors+Show Affiliations

Department of Urology, Urological Research Institute, University Vita-Salute San Raffaele, San Raffaele Scientific Institute, Milan, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22970988

Citation

Gandaglia, Giorgio, et al. "Postoperative Phosphodiesterase Type 5 Inhibitor Administration Increases the Rate of Urinary Continence Recovery After Bilateral Nerve-sparing Radical Prostatectomy." International Journal of Urology : Official Journal of the Japanese Urological Association, vol. 20, no. 4, 2013, pp. 413-9.
Gandaglia G, Albersen M, Suardi N, et al. Postoperative phosphodiesterase type 5 inhibitor administration increases the rate of urinary continence recovery after bilateral nerve-sparing radical prostatectomy. Int J Urol. 2013;20(4):413-9.
Gandaglia, G., Albersen, M., Suardi, N., Gallina, A., Abdollah, F., Castiglione, F., Capitanio, U., Salonia, A., Rigatti, P., Hedlund, P., Montorsi, F., & Briganti, A. (2013). Postoperative phosphodiesterase type 5 inhibitor administration increases the rate of urinary continence recovery after bilateral nerve-sparing radical prostatectomy. International Journal of Urology : Official Journal of the Japanese Urological Association, 20(4), 413-9. https://doi.org/10.1111/j.1442-2042.2012.03149.x
Gandaglia G, et al. Postoperative Phosphodiesterase Type 5 Inhibitor Administration Increases the Rate of Urinary Continence Recovery After Bilateral Nerve-sparing Radical Prostatectomy. Int J Urol. 2013;20(4):413-9. PubMed PMID: 22970988.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Postoperative phosphodiesterase type 5 inhibitor administration increases the rate of urinary continence recovery after bilateral nerve-sparing radical prostatectomy. AU - Gandaglia,Giorgio, AU - Albersen,Maarten, AU - Suardi,Nazareno, AU - Gallina,Andrea, AU - Abdollah,Firas, AU - Castiglione,Fabio, AU - Capitanio,Umberto, AU - Salonia,Andrea, AU - Rigatti,Patrizio, AU - Hedlund,Petter, AU - Montorsi,Francesco, AU - Briganti,Alberto, Y1 - 2012/09/12/ PY - 2012/06/06/received PY - 2012/08/10/accepted PY - 2012/9/14/entrez PY - 2012/9/14/pubmed PY - 2013/10/1/medline SP - 413 EP - 9 JF - International journal of urology : official journal of the Japanese Urological Association JO - Int J Urol VL - 20 IS - 4 N2 - OBJECTIVES: To investigate the effect of phosphodiesterase type 5 inhibitor on urinary continence recovery after bilateral nerve-sparing radical prostatectomy. METHODS: We analyzed data of 393 open bilateral nerve-sparing radical prostatectomies carried out between 2005 and 2010. Patients who recovered urinary continence within the first month after catheter removal (n = 52) were excluded. This resulted in 341 evaluable patients. Urinary continence recovery was defined as being completely pad free over a period of 24 h. Patients were stratified according to postoperative daily (n = 58; 17%), on-demand (n = 112; 32.8%) and no (n = 171; 50.1%) phosphodiesterase type 5 inhibitor use. The effect of phosphodiesterase type 5 inhibitor use on urinary continence was assessed using the Kaplan-Meier method. Uni- and multivariable Cox regression analyses were used to test the association between phosphodiesterase type 5 inhibitor and urinary continence recovery after adjusting for cofounders. RESULTS: At a mean follow up of 36.4 months after surgery (median: 33), 288 patients (84.5%) recovered urinary continence after bilateral nerve-sparing radical prostatectomy. Patients who did not use phosphodiesterase type 5 inhibitor after surgery had lower rates of urinary continence recovery at 1- and 2-year follow up as compared with patients taking phosphodiesterase type 5 inhibitor (67.1 vs 86.7% and 76 vs 94.4%, respectively; P < 0.001). After adjusting for all confounders, multivariable analysis showed that phosphodiesterase type 5 inhibitor use, either on demand or daily, had a positive impact on urinary continence recovery (P = 0.03). CONCLUSIONS: Patients taking phosphodiesterase type 5 inhibitor have higher urinary continence recovery rates as compared with patients left untreated after bilateral nerve-sparing radical prostatectomy. An improvement in sphincteric and pelvic floor blood supply might be responsible for this beneficial effect associated with the use of phosphodiesterase type 5 inhibitor. SN - 1442-2042 UR - https://www.unboundmedicine.com/medline/citation/22970988/Postoperative_phosphodiesterase_type_5_inhibitor_administration_increases_the_rate_of_urinary_continence_recovery_after_bilateral_nerve_sparing_radical_prostatectomy_ L2 - https://doi.org/10.1111/j.1442-2042.2012.03149.x DB - PRIME DP - Unbound Medicine ER -